Novo Nordisk (NVO) said Thursday it received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for an update of the Ozempic, or semaglutide, label to include risk reduction of kidney disease progression in adults with type 2 diabetes and chronic kidney disease.
In the FLOW trial, which assessed how effectively Ozempic reduces the risk of chronic kidney disease-related events, semaglutide 1.0 milligram showed a "statistically significant and superior" 24% risk reduction in kidney disease progression, and cardiovascular and kidney death, versus placebo, the company said.
Additionally, Novo Nordisk said it has filed for a label expansion in the US, with a decision expected in H1 2025.
Shares of Novo Nordisk were down 2.4% in recent Friday trading.
Price: 105.98, Change: -2.63, Percent Change: -2.42
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.